Equities research analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) to post sales of $5.67 million for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for CRISPR Therapeutics’ earnings, with the lowest sales estimate coming in at $330,000.00 and the highest estimate coming in at $16.80 million. CRISPR Therapeutics posted sales of $540,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 950%. The business is scheduled to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that CRISPR Therapeutics will report full year sales of $119.24 million for the current year, with estimates ranging from $1.32 million to $727.30 million. For the next year, analysts expect that the business will post sales of $198.94 million, with estimates ranging from $2.00 million to $384.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow CRISPR Therapeutics.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last announced its quarterly earnings results on Monday, February 14th. The company reported ($1.84) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.74) by ($0.10). The company had revenue of $12.90 million during the quarter, compared to analyst estimates of $5.39 million. CRISPR Therapeutics had a net margin of 41.28% and a return on equity of 16.21%.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC acquired a new position in CRISPR Therapeutics during the 2nd quarter worth $2,371,000. Thrivent Financial for Lutherans increased its holdings in CRISPR Therapeutics by 53.2% in the second quarter. Thrivent Financial for Lutherans now owns 3,956 shares of the company’s stock valued at $640,000 after buying an additional 1,373 shares during the last quarter. Kestra Advisory Services LLC increased its holdings in CRISPR Therapeutics by 2.2% in the third quarter. Kestra Advisory Services LLC now owns 12,472 shares of the company’s stock valued at $1,396,000 after buying an additional 272 shares during the last quarter. Avantax Advisory Services Inc. raised its stake in CRISPR Therapeutics by 15.6% during the third quarter. Avantax Advisory Services Inc. now owns 4,420 shares of the company’s stock valued at $494,000 after buying an additional 597 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its holdings in CRISPR Therapeutics by 13.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 50,810 shares of the company’s stock worth $5,599,000 after buying an additional 6,000 shares during the last quarter. 55.21% of the stock is currently owned by hedge funds and other institutional investors.
CRISPR Therapeutics stock traded up $0.34 during midday trading on Friday, reaching $64.89. The stock had a trading volume of 26,829 shares, compared to its average volume of 1,598,174. The stock’s 50-day simple moving average is $61.76 and its 200 day simple moving average is $75.45. CRISPR Therapeutics has a twelve month low of $50.54 and a twelve month high of $169.76. The stock has a market capitalization of $4.97 billion, a PE ratio of 14.60 and a beta of 2.02.
CRISPR Therapeutics Company Profile (Get Rating)
CRISPR Therapeutics AG, a gene-editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene-editing technology that allows for precise directed changes to genomic DNA.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.